Q/C Technologies Inc

QCLS

Market cap $30.2M

New York, NY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C Technologies” or “the Company”), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Chelsea Voss to its Board of Directors. Ms. Voss is a computer scientist and Member of Technical Staff at OpenAI, where she has played a key role in the development, evaluation, and launch of some of the most advanced, widely used artificial intelligence systems.

New York, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C” or “the Company”), a pioneer of quantum-class computing at the speed of light, today announced that Martin Shkreli become a Strategic Advisor to the Company, contributing his experience in technology, industry contacts, financial innovation and early-stage growth.

Q/C Technologies In (NASDAQ: QCLS) soared another 60% on Thursday morning after former pharmaceutical executive Martin Shkreli touted the company as a “long idea”. According to him, the photonic computing firm could be trading at $100 per share, and that too in the near-term.

Breakthrough LPUs designed to compute at quantum-class speed using natural light instead of electrical signals to achieve quantum computer speeds

Dr. Frankel brings extensive knowledge and deep expertise that bridges advanced physics and quantum technologies New York, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C” or the “Company”), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Steven Frankel, Ph.D. as Senior Quantum Advisor.

NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“Q/C” or the “Company”) today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin trading under the new ticker symbol “QCLS” on the Nasdaq Capital Market, effective as of the market open on Thursday, September 25, 2025. Until then, the Company's common stock will continue to trade under its current ticker symbol “TNFA.” The new name Q/C Technologies represents the Company's recent strategi.

NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals Inc. (Nasdaq: TNFA), (“TNF” or the “Company”) today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule, the Company's shares maintained the minimum bid price of $1.00 for 10 consecutive business days. "We are pleased to have.

NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced its participation in the H.C. Wainwright & Co. 27th Annual Global Investment Conference taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. TNF's presentation is scheduled for Wednesday, September 10, 2025, at 8:00 a.m. ET. Presentation Details: Date and time: September 10, 2025, at 8:00 a.m. ET1 Location: Lotte New York Palace Hotel, New York City.

NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced the closing of a $7.0 million private placement financing of convertible preferred stock with the Company's largest strategic stockholder and other existing stockholders. The private placement involved the sale of 7,000 shares of preferred stock, with a stated value of $1,000 per share, convertible into 1,400,000 million shares of the Company's common stock at an initial conversion price.

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNFA, “TNF”) by an additional $3 million. The Company does so to help support TNF's recent acquisition of a license with LightSolver, Ltd. (“LightSolver”), a company recognized by Gartner and the World Economic Forum for its breakthrough innovations. The license is for its revolutionary processing accelerator designed.